{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:01:24Z","timestamp":1790355684724,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2016.03.002","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:39:40Z","timestamp":1457656780000},"page":"2121-2128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae"],"prefix":"10.1016","volume":"34","author":[{"given":"Michael","family":"Lebens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Terrinoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan L.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Larena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gustafsson-Hedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"K\u00e4llg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.03.002_bib0195","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0200","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0205","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0210","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.coi.2012.03.014","article-title":"Vaccines against mucosal infections","volume":"24","author":"Holmgren","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0215","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.vaccine.2004.11.010","article-title":"Mucosal adjuvants","volume":"23","author":"Freytag","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0220","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00018-008-7496-5","article-title":"Cholera toxin structure, gene regulation and pathophysiological and immunological aspects","volume":"65","author":"Sanchez","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0225","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrgastro.2011.174","article-title":"New-generation vaccines against cholera","volume":"8","author":"Clemens","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0230","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","article-title":"Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling","volume":"194","author":"Larena","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0235","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0240","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.vaccine.2013.03.027","volume":"31","author":"Holmgren","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0245","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0250","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0255","series-title":"Phase I Study of ETEC vaccine","author":"NIAID","year":"2010"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0260","series-title":"Safety, immunogenicity and efficacy study of live attenuated ETEC vaccine ACE527 with and without dmLT adjuvant in adults","author":"PATH","year":"2012"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0265","doi-asserted-by":"publisher","first-page":"e108521","DOI":"10.1371\/journal.pone.0108521","article-title":"Development of Stable Vibrio cholerae O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens","volume":"9","author":"Karlsson","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0270","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1016\/j.vaccine.2011.06.121","article-title":"Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens","volume":"29","author":"Lebens","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0275","first-page":"111","article-title":"Expression and detection of different biotype-associated cell-bound haemagglutinins of Vibrio cholerae O1","volume":"135","author":"Jonson","year":"1989","journal-title":"J General Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0280","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1073\/pnas.86.2.481","article-title":"Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development","volume":"86","author":"Sanchez","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0285","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(88)90120-1","article-title":"Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR","volume":"27","author":"Levine","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0290","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/0076-6879(94)35157-0","article-title":"Analysis and construction of stable phenotypes in gram-negative bacteria with Tn5- and Tn10-derived minitransposons","volume":"235","author":"de Lorenzo","year":"1994","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0295","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/nar\/16.1.355","article-title":"The nucleotide sequence of pACYC184","volume":"16","author":"Rose","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0300","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/mpat.2000.0436","article-title":"The role of different protein components from the Haemophilus ducreyi cytolethal distending toxin in the generation of cell toxicity","volume":"30","author":"Frisk","year":"2001","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0305","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/nbt1293-1574","article-title":"Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines","volume":"11","author":"Lebens","year":"1993","journal-title":"Biotechnology"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0310","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/IAI.20.2.552-558.1978","article-title":"Purification of cholera toxin and its subunits: new methods of preparation and the use of hypertoxinogenic mutants","volume":"20","author":"Mekalanos","year":"1978","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0315","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4049\/jimmunol.96.3.440","article-title":"Pathogenesis of experimental cholera: biologic ativities of purified procholeragen A","volume":"96","author":"Finkelstein","year":"1966","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0320","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/JCM.17.4.596-600.1983","article-title":"Rapid GM1-enzyme-linked immunosorbent assay with visual reading for identification of Escherichia coli heat-labile enterotoxin","volume":"17","author":"Svennerholm","year":"1983","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0325","first-page":"23","article-title":"Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin","volume":"64","author":"Svennerholm","year":"1986","journal-title":"Med Biol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0330","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ejpb.2011.06.009","article-title":"Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation","volume":"79","author":"Borde","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0335","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/IAI.15.3.704-712.1977","article-title":"Intestinal fluid accumulation induced by oral challenge with Vibrio cholerae or cholera toxin in infant mice","volume":"15","author":"Baselski","year":"1977","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0340","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.4049\/jimmunol.164.9.4706","article-title":"DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323\u2013339 epitope","volume":"164","author":"Robertson","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0345","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/IAI.66.2.514-520.1998","article-title":"Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates","volume":"66","author":"Johansson","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0350","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.4049\/jimmunol.0803992","article-title":"CD11c (high) dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization","volume":"183","author":"Fahlen-Yrlid","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0355","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/S0021-9258(18)50491-9","article-title":"Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition","volume":"254","author":"Mekalanos","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0360","doi-asserted-by":"publisher","first-page":"16555","DOI":"10.1074\/jbc.M110.211078","article-title":"Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteases","volume":"286","author":"Sikora","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0365","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0092-8674(01)00289-6","article-title":"Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin","volume":"104","author":"Tsai","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0370","first-page":"301","article-title":"Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens","volume":"59","author":"Lycke","year":"1986","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0375","first-page":"323","article-title":"Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant","volume":"72","author":"Clarke","year":"1991","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2016.03.002_bib0380","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.4049\/jimmunol.132.6.2736","article-title":"Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin","volume":"132","author":"Elson","year":"1984","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16002796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:53:11Z","timestamp":1692237191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16002796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":38,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X16002796"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}